REPL Replimune Group, Inc.

Nasdaq replimune.com


$ 4.60 $ 0.39 (8.97 %)    

Wednesday, 15-Oct-2025 19:02:03 EDT
QQQ $ 602.32 $ 4.22 (0.71 %)
DIA $ 463.02 $ 0.00 (0 %)
SPY $ 664.84 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.55 $ 6.60 (1.73 %)
$ 4.74
$ 4.38
$ 4.59 x 482
$ 4.74 x 10
$ 4.36 - $ 4.75
$ 2.68 - $ 17.00
3,703,482
na
369.98M
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-22-2025 03-31-2025 10-K
3 02-12-2025 12-31-2024 10-Q
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-16-2024 03-31-2024 10-K
7 02-08-2024 12-31-2023 10-Q
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-18-2023 03-31-2023 10-K
11 02-09-2023 12-31-2022 10-Q
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-19-2022 03-31-2022 10-K
15 02-03-2022 12-31-2021 10-Q
16 11-04-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-20-2021 03-31-2021 10-K
19 02-04-2021 12-31-2020 10-Q
20 11-05-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 06-03-2020 03-31-2020 10-K
23 02-13-2020 12-31-2019 10-Q
24 11-12-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 06-28-2019 03-31-2019 10-K
27 02-14-2019 12-31-2018 10-Q
28 11-14-2018 09-30-2018 10-Q
29 08-30-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-downgrades-replimune-group-to-underweight

JP Morgan analyst Anupam Rama downgrades Replimune Group (NASDAQ:REPL) from Neutral to Underweight.

 replimune-group-completes-type-a-meeting-with-fda-on-rp1-bla-for-advanced-melanoma-path-forward-for-accelerated-approval-still-undetermined

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immun...

 hc-wainwright--co-reiterates-neutral-on-replimune-groupto-neutral

HC Wainwright & Co. analyst Robert Burns reiterates Replimune Group (NASDAQ:REPL) from Neutral to Neutral.

 replimune-group-q1-eps-095-misses-084-estimate

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0...

 why-is-replimune-stock-trading-lower-on-monday

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION